We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: SGLT2 inhibitors
MedXY News
EnglishTag

SGLT2 inhibitors

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

SGLT2 Inhibitors Enhance Recovery After Endovascular Thrombectomy in Diabetic Stroke Patients: A Multicenter Retrospective Study
Diabetes & Endocrinologydiabetic strokeSGLT2 inhibitors

SGLT2 Inhibitors Enhance Recovery After Endovascular Thrombectomy in Diabetic Stroke Patients: A Multicenter Retrospective Study

By MedXY|Sep 18, 2026

SGLT2 inhibitors administered after endovascular thrombectomy in diabetic stroke patients significantly improve 3-month functional outcomes, suggesting a promising adjunctive therapy for poststroke diabetes management.

Ketoacidosis Risk with SGLT2 Inhibitors in Type 2 Diabetes: Insights from a Scandinavian Cohort Study
Diabetes & Endocrinologytype 2 diabetes
ketoacidosis

Ketoacidosis Risk with SGLT2 Inhibitors in Type 2 Diabetes: Insights from a Scandinavian Cohort Study

By MedXY|Sep 5, 2026

A large Scandinavian study reveals that ketoacidosis risk during SGLT2 inhibitor therapy in type 2 diabetes varies by patient factors and persists beyond early treatment, highlighting the need for ongoing risk assessment and management stra

Unveiling Heart Failure with Preserved Ejection Fraction in Adults with Congenital Heart Disease: Prevalence, Characteristics, and Clinical Challenges
Cardiologycongenital heart diseaseHFpEF

Unveiling Heart Failure with Preserved Ejection Fraction in Adults with Congenital Heart Disease: Prevalence, Characteristics, and Clinical Challenges

By MedXY|Aug 12, 2026

This article explores the high prevalence of heart failure with preserved ejection fraction (HFpEF) in adults with congenital heart disease (ACHD), highlighting its clinical features, hospitalization burden, and under-treatment issues.

Dapagliflozin and Lipoprotein Metabolism in Type 2 Diabetes: Preserving LDL Catabolism and Normalizing VLDL Processing
CardiologyDapagliflozinLDL catabolism

Dapagliflozin and Lipoprotein Metabolism in Type 2 Diabetes: Preserving LDL Catabolism and Normalizing VLDL Processing

By MedXY|Jul 31, 2026

This study demonstrates that dapagliflozin does not impair LDL catabolism but favorably shifts VLDL1 and VLDL2 catabolism toward normal physiology in type 2 diabetes, potentially contributing to reduced atherosclerosis risk.

SGLT2 Inhibitors Linked to Lower Lung Cancer Risk in Patients With COPD and Type 2 Diabetes
Diabetes & EndocrinologySGLT2 inhibitorslung cancer

SGLT2 Inhibitors Linked to Lower Lung Cancer Risk in Patients With COPD and Type 2 Diabetes

By MedXY|Jul 29, 2026

A nationwide cohort study found that SGLT2 inhibitor initiation was associated with a 27% lower risk of incident lung cancer in patients with COPD and type 2 diabetes compared with sulfonylureas.

Adjunctive SGLT2 Inhibitors with Progestins Reduce Endometrial Cancer Risk in Benign Uterine Conditions: Insights from a Large Real-World Study
newsprogestin therapybenign uterine disease

Adjunctive SGLT2 Inhibitors with Progestins Reduce Endometrial Cancer Risk in Benign Uterine Conditions: Insights from a Large Real-World Study

By MedXY|Aug 18, 2026

A large retrospective study demonstrates that adding SGLT2 inhibitors to progestin therapy in women with benign uterine diseases reduces the risk of developing endometrial cancer and the need for hysterectomy.

Individual GLP-1 Receptor Agonists and SGLT2 Inhibitors Show Largely Comparable Cardiovascular Protection in Type 2 Diabetes
Cardiologycardiovascular outcomesGLP-1 receptor agonists

Individual GLP-1 Receptor Agonists and SGLT2 Inhibitors Show Largely Comparable Cardiovascular Protection in Type 2 Diabetes

By MedXY|Jun 10, 2026

A multinational real-world study found broadly similar cardiovascular effectiveness across individual GLP-1 receptor agonists and SGLT2 inhibitors in metformin-treated type 2 diabetes, including among patients with established cardiovascula

Precision Prescribing of SGLT2 Inhibitors in Type 2 Diabetes for Primary Prevention of Heart Failure
Cardiologyheart failure preventionSGLT2 inhibitors

Precision Prescribing of SGLT2 Inhibitors in Type 2 Diabetes for Primary Prevention of Heart Failure

By MedXY|Jun 10, 2026

A validation study developed SABRE, a model that estimates how much SGLT2 inhibitors can reduce heart failure risk in people with type 2 diabetes, helping clinicians target preventive treatment more precisely.

Precision Prescribing of SGLT2 Inhibitors in People With Type 2 Diabetes for Primary Prevention of Heart Failure: Model Development and Validation Study
Cardiologycardiovascular riskheart failure prevention

Precision Prescribing of SGLT2 Inhibitors in People With Type 2 Diabetes for Primary Prevention of Heart Failure: Model Development and Validation Study

By MedXY|Jun 10, 2026

The SABRE model estimates which people with type 2 diabetes may benefit most from SGLT2 inhibitors to prevent heart failure before it develops.

Precision Prescribing of SGLT2 Inhibitors in Type 2 Diabetes for Primary Prevention of Heart Failure
Cardiologyheart failure preventionprecision medicine

Precision Prescribing of SGLT2 Inhibitors in Type 2 Diabetes for Primary Prevention of Heart Failure

By MedXY|Jun 3, 2026

A validated model, SABRE, estimates who with type 2 diabetes may gain the most heart-failure prevention benefit from SGLT2 inhibitors, enabling more precise, individualized prescribing.

No Clear Winner: Real-World Evidence Shows GLP-1RAs and SGLT2 Inhibitors Deliver Comparable Cardiovascular Benefits in Type 2 Diabetes
Cardiologycardiovascular outcomescomparative effectiveness

No Clear Winner: Real-World Evidence Shows GLP-1RAs and SGLT2 Inhibitors Deliver Comparable Cardiovascular Benefits in Type 2 Diabetes

By MedXY|Apr 18, 2026

A large-scale multinational study of over 1.2 million patients reveals that individual GLP-1 receptor agonists and SGLT2 inhibitors offer broadly similar cardiovascular protection in type 2 diabetes, challenging assumptions about meaningful

SGLT2 Inhibitors Do Not Increase Amputation Risk in Diabetic Foot Ulcer: Study Reveals Significant Mortality Benefit
Diabetes & Endocrinologyamputationdiabetic foot ulcer

SGLT2 Inhibitors Do Not Increase Amputation Risk in Diabetic Foot Ulcer: Study Reveals Significant Mortality Benefit

By MedXY|Apr 6, 2026

A retrospective study of 452 diabetic foot ulcer patients found that SGLT2 inhibitor use was not associated with increased amputation risk at 1 year and was linked to significantly lower mortality (1.1% vs 9.2%) and faster wound healing (44

Interaction Between SGLT2 Inhibition and Dietary Sodium: Insights from the CREDENCE Trial Post Hoc Analysis
CardiologyCanagliflozinchronic kidney disease

Interaction Between SGLT2 Inhibition and Dietary Sodium: Insights from the CREDENCE Trial Post Hoc Analysis

By MedXY|Mar 15, 2026

This post hoc analysis of the CREDENCE trial reveals that low-normal sodium intake increases cardiovascular risk in T2D and CKD, a risk significantly mitigated by canagliflozin, while renal protection remains consistent across sodium intake

Uncoupling Metabolic Benefit from Glycemic Control: Empagliflozin’s Superiority Over Insulin in Beta Cell Preservation
Clinical UpdatesBeta-cell functioninsulin sensitivity

Uncoupling Metabolic Benefit from Glycemic Control: Empagliflozin’s Superiority Over Insulin in Beta Cell Preservation

By MedXY|Mar 13, 2026

A randomized cross-over trial reveals that empagliflozin enhances beta cell function and insulin sensitivity more effectively than titrated insulin, suggesting benefits beyond simple glucotoxicity relief.

SGLT2 Inhibitors Reduce Gout-Related Medication Burden in Patients with Type 2 Diabetes
Diabetes & Endocrinologygoutpolypharmacy

SGLT2 Inhibitors Reduce Gout-Related Medication Burden in Patients with Type 2 Diabetes

By MedXY|Mar 6, 2026

A large-scale target trial emulation study demonstrates that SGLT2 inhibitors significantly reduce the initiation of allopurinol and the use of anti-inflammatory medications in patients with comorbid gout and type 2 diabetes, offering a pot

SGLT2 Inhibition and Atrial Fibrillation Recurrence Post-Ablation: Insights from the DARE-AF Randomized Clinical Trial
Cardiologyatrial fibrillationcatheter ablation

SGLT2 Inhibition and Atrial Fibrillation Recurrence Post-Ablation: Insights from the DARE-AF Randomized Clinical Trial

By MedXY|Mar 3, 2026

The DARE-AF trial demonstrates that 10 mg of dapagliflozin for three months does not significantly reduce early arrhythmia recurrence or AF burden following catheter ablation in patients without existing indications for SGLT2 inhibitors.

SGLT2 Inhibitors for All? Meta-Analysis Confirms Broad Clinical Benefits Regardless of Diabetes or Albuminuria Levels
Diabetes & Endocrinologyalbuminuriachronic kidney disease

SGLT2 Inhibitors for All? Meta-Analysis Confirms Broad Clinical Benefits Regardless of Diabetes or Albuminuria Levels

By MedXY|Feb 9, 2026

A large-scale meta-analysis reveals that SGLT2 inhibitors significantly reduce kidney disease progression, AKI, and hospitalizations in patients with CKD, independent of diabetes status or baseline albuminuria.

Beyond Insulin: GLP-1 and SGLT2 Inhibitor Combination Therapy Targets Obesity and Kidney Disease in Type 1 Diabetes
Diabetes & Endocrinologychronic kidney diseaseGLP-1 receptor agonists

Beyond Insulin: GLP-1 and SGLT2 Inhibitor Combination Therapy Targets Obesity and Kidney Disease in Type 1 Diabetes

By MedXY|Feb 4, 2026

A pilot study shows that combining GLP-1 analogues and SGLT2 inhibitors with lifestyle changes significantly reduces body weight and albuminuria in overweight Type 1 diabetes patients with CKD, though glycemic and blood pressure improvement

Beyond Glycemic Control: How SGLT2 and DPP-4 Inhibitor Combinations Rescue the Urinary Microbiome in Type 2 Diabetes
Diabetes & EndocrinologyDPP‑4 inhibitorsSGLT2 inhibitors

Beyond Glycemic Control: How SGLT2 and DPP-4 Inhibitor Combinations Rescue the Urinary Microbiome in Type 2 Diabetes

By MedXY|Feb 4, 2026

A new study reveals that combining Empagliflozin with Linagliptin reverses urinary dysbiosis in T2D patients, potentially reducing the risk of urogenital infections and improving treatment adherence compared to SGLT2 inhibitor monotherapy.

Beyond Glycemic Control: Empagliflozin/Linagliptin Combination Restores Urinary Microbiota Homeostasis in Type 2 Diabetes
Diabetes & EndocrinologyDPP‑4 inhibitorsSGLT2 inhibitors

Beyond Glycemic Control: Empagliflozin/Linagliptin Combination Restores Urinary Microbiota Homeostasis in Type 2 Diabetes

By MedXY|Feb 3, 2026

A randomized clinical study demonstrates that while SGLT2 inhibitors alone may induce urinary dysbiosis and increase pathogen risk, combining them with DPP-4 inhibitors restores a healthy urinary microbiota, potentially improving patient co

1 / 3
123
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities